Craig Shepherd joined the Medcan Board of Directors in September, 2011 and serves as Chair of its Corporate Responsibility Committee. Craig is Managing Director and Chief Legal Officer of DRI Capital, a life sciences private equity firm with over $3 billion under management through its funds Drug Royalty I, II, II Co-Investment Fund and III. Craig leads DRI’s business development, legal, and strategic planning functions, focusing on the worldwide sourcing, evaluation, acquisition and financing of healthcare royalties and also serves on the firm’s Investment Committee.
Prior to joining DRI Capital in 2010, Craig held roles of progressive responsibility at Amgen based at global headquarters in California and international headquarters in Switzerland. These included Executive Director and Associate General Counsel, with legal responsibility for the US Nephrology Business Unit and Amgen Canada, where he served on the executive committee for both business units; Senior Counsel to Amgen Europe/International, where he worked in health systems across more than 35 country markets; Counsel to Amgen USA, and an intern in Amgen product licensing. Craig began his legal career with Morgan Lewis LLP in the United States and McCarthy Tétrault in Canada. Licensed to practise law in California and in Ontario, Craig holds an MBA from Harvard University, an LLB from McGill University and a BA from the University of Western Ontario. Craig also serves on the boards of Drug Royalty III GP and the American Kidney Fund, where he is a member of the board Finance and Public Support Committees.